Since for patients with hormone receptor-negative and HER2-negative metastatic BC, especially in cases of absent BRCA1/2 mutations, only a few targeted agents are available, a new antibody–drug conjugate was recently developed, trastuzumab deruxtecan, specifically directed towards HER2. This evidence concerns the gene ERBB2 and breast cancer.